

# A Rosendorff, MD

## ***CLINICAL INTERESTS***

---

- Molecular diagnostics of hemoglobin disorders
- Clinical immunology
- Clinical microbiology
- Mass spec for therapeutic drug monitoring
- Next-generation sequencing approaches to diagnosis in virology

## ***EDUCATION AND TRAINING***

---

1988-1993 **BA, BA Hons** University of the Witwatersrand, Johannesburg, South Africa  
 1995-2000 **MD** Mount Sinai School of Medicine, New York, NY  
**2000-2005** Brigham and Women's Hospital and Harvard University, Boston MA **Postdoctoral fellowship in infectious diseases**  
 2005-2008 **Resident in Clinical Pathology**, Brigham and Women's Hospital, Boston, MA

## ***APPOINTMENTS AND POSITIONS***

---

4/2013- **Laboratory Director**, Therasys Inc, Palo Alto, CA

- Direct high complexity CLIA licensed laboratory
- Oversee 20 direct reports: CLSes, Techs, TS and GS
- Worked extensively with R&D leads and directed laboratory staff, to devise and validate novel laboratory assays in molecular diagnostics, general chemistry and hematology
- Established technical performance of over 70 novel assay methods
- Successfully led laboratory through state (CA, NYS) and federal (CLIA) lab inspections
- Provided regulatory guidance on CLIA and state laboratory compliance

2008-2013 **Assistant Professor of Pathology**, Department of Pathology, University of Pittsburgh, Pittsburgh, PA  
**Medical Director**, Clinical Laboratories, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA  
**Founder and Director**, Hemoglobin Diagnostics Service, UPMC.

## ***PROFESSIONAL CERTIFICATION AND LICENSURE***

---

2013- Medical License, Medical Board of California  
 2013- Medical License, Arizona Medical Board  
 2008- Board Certification, Clinical Pathology (08-425)  
 2008- Pennsylvania Medical License (MD435621)

# A Rosendorff, MD

2008- Commonwealth of Massachusetts Medical License (Inactive)

## ***MEMBERSHIPS IN PROFESSIONAL SOCIETIES***

---

2008- American Society for Clinical Pathology (ASCP)  
2008- College of American Pathologists (CAP)  
2008- Society for Pediatric Pathology  
2007- Academy of Clinical Laboratory and Physician Scientists (ACLPS)

## ***PRIZES AND AWARDS***

---

2009- Howard Hughes Medical Institute Physician-Scientist Early Career Award  
2002-2005 Leukemia and Lymphoma Society (LLS), Grant Awardee (Fellow),  
2000 Morris B Bender Family Prize for Clinical Neurology,  
1998-1999 Howard Hughes Medical Institute Research Training Fellowship  
1992- Faculty of Arts Gold Medal, University of the Witwatersrand  
1988- University Council Entrance Scholarship

## ***INVITED REVIEWER ACTIVITY***

---

2012- Ad-Hoc Reviewer, Current Microbiology  
2012- Ad-Hoc Reviewer, Cellular Physiology and Biochemistry (Karger)  
2011- European Journal of Immunology  
2009- Ad-Hoc Reviewer, Journal of Pediatric Pathology  
2008- Reviewer, CDC Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) grants, Atlanta, GA,

## ***UNIVERSITY ACTIVITIES***

---

2012- Chair, Clinical Laboratory Standards Committee (CHP)  
2010- Clinical Pathology Rotation Director: Pathology Residency (Junior Lab Director Program) and Pediatric Pathology Fellowship  
2009- Physician representative, Executive Patient-Safety Committee (CHP)  
2008- Member: Molecular Virology Program, UPCI  
2008- Lecturer: Molecular Virology graduate course (Tumor Virology), UPCI and Hillman Cancer Center

## ***MEETINGS AND ABSTRACTS (2012)***

---

2012- International Conference on Oncogenic Herpesviruses and Associated Diseases, Philadelphia, PA, August 1-4, 2012) Epstein-Barr virus (EBV) ZTA interacts with histone modifying proteins

# A Rosendorff, MD

MLL2 and JMJD2C to create an epigenetic footprint favoring lytic replication Taylor GM and **Rosendorff A**

2012- *Proteomics, Interactomes*. May 7-May 12, 2012, Stockholm, Sweden (Keystone Conferences) Epstein-Barr virus (EBV) ZTA interacts with histone modifying proteins MLL2 and JMJD2C to create an epigenetic footprint favoring lytic replication Taylor GM and **Rosendorff A**

2012- AACR "Mass Spectrometry in the Clinical Lab: Best Practices and Current Applications" September 6-7, Chicago, IL.

## GRANT FUNDING

---

2008-2014 Howard Hughes Medical Institute, Physician-Scientist Early Career Award

## PUBLICATIONS

---

- (1) Ami P. Shah, M.D., M.P.H; Benjamin T. Cobb; Darla R. Lower, MT(ASCP); Nader Shaikh, M.D.; Jayne Rasmussen, MPM, MT(ASCP); Alejandro Hoberman, M.D.; Ellen R. Wald, M.D.; **Adam Rosendorff, M.D.**; Robert W. Hickey, M.D. Enhanced vs. Automated Urinalysis for screening of Urinary Tract Infections in Children in the Emergency Department. (*Pediatr Infect Dis J*. 2014 Mar;33(3):272-5.)
- (2) **Adam Rosendorff**, Comparison of CEDIA FK506 assay with HPLC/MS/MS in a large cohort of pediatric patients (*Am J Clin Pathol*. 2013 Jun;139(6):788-92)
- (3) Maurer S, **Rosendorff A** Hemoglobin Pittsburgh: Spurious hypoxemia by pulse oximetry due to a novel alpha-chain hemoglobin variant in a 12 year-old boy (submitted, *American Journal of Clinical Pathology*)
- (4) Activated Partial Thromboplastin Time is a Better Trending Tool in Pediatric ECMO Timothy M. Maul TM, Wolff EL, **Rosendorff A**, Morell VO and Wearden PD, *Pediatr Crit Care Med*. 2012 Nov;13(6):e363-71. doi: 10.1097/PCC.0b013e31825b582e.
- (5) Taylor GM, Raghuwanshi SK, Wadowsky R, Rowe DT **Rosendorff, A** Endoplasmic Reticulum Stress Causes EBV lytic replication *Blood* August 17, 2011
- (6) Davies ML, Xu S, Lyons-Weiler J, **Rosendorff A**, Webber SA, Wasil LR, Metes D, Rowe DT. (2010) Cellular factors associated with latency and spontaneous Epstein-Barr virus reactivation in B-lymphoblastoid cell lines. *Virology*. 400:53-67
- (7) Garrido J, Maruo S, Takada K, **Rosendorff A** EBNA3C interacts with Gadd34 and counteracts the unfolded protein response. *Virology*. 2009 Dec 29;6(1):231.

# A Rosendorff, MD

- (8) **Rosendorff, A** and Dorfman, DD Factor V<sub>Leiden</sub>: a review Arch Pathol Lab Med. 2007 Jun;131(6):866-71.
- (9) Portal D, **Rosendorff A**, Kieff E Epstein-Barr nuclear antigen leader protein co-activates transcription through interaction with histone deacetylase 4. Proc Natl Acad Sci USA 2006 103(51): 19278-83.
- (10) **Rosendorff A**, Sakakibara S, Lu S, Kieff E, Xuan Y, DiBacco A, Shi Y, Shi Y and Gill G NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5308-13.
- (11) **Rosendorff A**, David G, Lin J, Kieff E and Johannsen E. EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J Virol. 2004 Jan;78(1):367-77.
- (12) **Rosendorff A**, Ebersole BJ, Sealton S. Conserved helix 7 tyrosine functions as an activation relay in the serotonin 5HT<sub>2C</sub> receptor Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):90-6.
- (13) Chu JL, Ramos P, **Rosendorff A**, Nikolic-Zugic J, Lacy E, Matsuzawa A, Elkon KB. "Massive upregulation of Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome." J. Exp. Med. 1995;181:393-398.

## **REFERENCES:**

Available upon request